Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonvendi vs. Lysteda for Menorrhagia in Von Willebrand Disease
NCT02606045Phase 3Terminated
- Start
- Feb 2019
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of von Willebrand factor concentrate in von Willebrand disease (VWD) (2 arms). Primary endpoint: Pictorial Blood Assessment Chart at 4 weeks. Started Feb 2019; status: terminated.
02
Drugs
von Willebrand factor concentrate
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NCT02606045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02606045.